Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02985541 · ClinicalTrials.gov registry record · Phase 3
Mirena Extension Trial
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 364
- Enrollment target
NCT02985541 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 364 participants.
The verdict
NCT02985541, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 364 participants
- Enrollment target
Study Summary
The study is performed to assess if Mirena is effective and safe as a birth control method beyond 5 years of use. Further the menstrual blood loss (in women that had Mirena inserted for the indication heavy menstrual bleeding \[HMB\]) and safety will be assessed.
Interventions
- DRUG Levonorgestrel IUS (Mirena, BAY86-5028)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 364 participants |
| Start Date | 2016-12-22 |
| Est. Completion | 2021-05-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02985541
The ClinicalTrials.gov registry entry for NCT02985541 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 364 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Levonorgestrel IUS (Mirena, BAY86-5028) is the first listed.
NCT02985541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02985541 about?
NCT02985541 is a clinical study titled "Mirena Extension Trial". The study is performed to assess if Mirena is effective and safe as a birth control method beyond 5 years of use. Further the menstrual blood loss (in women that had Mirena inserted for the indication heavy menstrual bleeding \[HMB\]) and safety will be assessed.
What is the current status of trial NCT02985541?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 364 participants. The study started on 2016-12-22. Estimated completion is 2021-05-28.
What interventions are being tested in trial NCT02985541?
The interventions under investigation include: Levonorgestrel IUS (Mirena, BAY86-5028) (DRUG).
Who is sponsoring clinical trial NCT02985541?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.